Supplementary Materials

This PDF file includes:

  • Fig. S1. Representative images of all clinical HAV explants stained with H&E.
  • Fig. S2. Representative images of all clinical HAV explants immunostained for expression of CD3 and CD20.
  • Fig. S3. Representative images of all clinical HAV explants immunostained for expression of CD206, CD80, and CD68.
  • Fig. S4. Representative images of all clinical HAV explants immunostained for expression of αSMA and CNN1.
  • Fig. S5. Representative images of all clinical HAV explants immunostained for expression of CD31 and CD34.
  • Fig. S6. Representative images of all clinical HAV explants immunostained for expression of αSMA and Nestin.
  • Fig. S7. Immunofluorescence staining of αSMA and CD31 in 16-week HAV explant.
  • Fig. S8. αSMA+/Nestin+ cells participate in HAV self-healing and repair after cannulation injury.
  • Fig. S9. Representative images of all clinical HAV explants immunostained for expression of αSMA and CD90.
  • Fig. S10. Additional immunofluorescence characterization of CD90+ cells in 200-week HAV explant.
  • Fig. S11. Summary diagram illustrating host cell repopulation and maturation within HAV after implantation.
  • Table S1. Summary of all clinical HAV explants from phase 2 clinical trials.
  • Table S2. Antibodies used and application conditions.

[Download PDF]